Comparative Pharmacology
Head-to-head clinical analysis: GLYCOPYRROLATE versus LUSEDRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLYCOPYRROLATE versus LUSEDRA.
GLYCOPYRROLATE vs LUSEDRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glycopyrrolate is a quaternary ammonium anticholinergic agent that competitively antagonizes acetylcholine at muscarinic receptors in the autonomic nervous system, thereby reducing salivary, gastric, and bronchial secretions. It also exhibits antispasmodic effects on gastrointestinal smooth muscle.
LUSEDRA (valbenazine) is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor. It reduces presynaptic dopamine release by inhibiting VMAT2, thereby reducing dopamine neurotransmission in the striatum.
1-2 mg orally 2-3 times daily; maximum 8 mg/day. For parenteral use: 0.1-0.2 mg IV/IM every 4-6 hours as needed.
5 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 0.6-1.2 hours (IM/IV), with prolonged duration in elderly and renal impairment.
8-12 hours (terminal, prolonged in renal impairment; dose adjustment needed if CrCl <30 mL/min).
Primarily renal excretion of unchanged drug (85-90%) with biliary/fecal elimination accounting for <10%.
Primarily renal (70-80% as unchanged drug); 20-30% via biliary/fecal.
Category C
Category C
Anticholinergic
Anticholinergic